Business
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the recent completion of enrollment in the U.S. Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity (NCT06679959). All 65 participants are obese or overweight with at least one weight-related comorbidity.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.","length":304,"tagName":"p"},{"type":"text","content":"- The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration.","length":216,"tagName":"p"},{"type":"text","content":"- Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depot treatment formulation are expected in the first quarter of 2026.","length":143,"tagName":"p"},{"type":"text","content":"- The Company will host a conference call in Mandarin today at 10:00 a.m. China Standard Time.","length":99,"tagName":"p"},{"type":"text","content":"HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the recent completion of enrollment in the U.S. Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity (NCT06679959). All 65 participants are obese or overweight with at least one weight-related comorbidity.","length":496,"tagName":"p"},{"type":"text","content":"The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomized, double-blind, placebo-controlled and multi-center study conducted in the U.S. to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. The study consists of three cohorts of different doses, with a total of 65 participants. Topline data are expected in the first quarter of 2026.","length":570,"tagName":"p"},{"type":"text","content":"The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life (as measured by time to 50% Cmax) in participants with obesity in the Phase Ib study ...